Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
CTXR Stock — Citius Pharmaceuticals Inc
Citius Pharmaceuticals Inc (CTXR)
Updated October 16, 2026.
CTXR is a Stock. Total return is -99.9% over the past 12 years, 479.1 points behind SPY at 379.2%.
Citius Pharmaceuticals is a biopharmaceutical company developing critical care products, including its FDA-approved immunotherapy LYMPHIR for cutaneous T-cell lymphoma and late-stage pipeline candidates for catheter-related bloodstream infections, hemorrhoid relief, and acute respiratory distress syndrome. The company does not currently distribute dividends to shareholders. This security appeals to investors seeking exposure to clinical-stage and early-commercial biopharmaceutical development rather than income generation.
CTXR dividend yield and income
Price as of 2026-10-16.
The payment date is 06/09/2017.
CTXR performance versus SPY
Price and return data through 2026-10-16.
Total return is -99.9% over the past 12 years, 479.1 points behind SPY at 379.2%. Over the past year its total return — price change plus distributions reinvested — is -68.9%. Its deepest 1-year drawdown was 74.7%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -17.9% | — |
| 3M | -10.0% | — |
| 6M | -46.2% | — |
| YTD | -40.8% | — |
| 1Y | -68.9% | — |
| 2Y CAGR | — | -78.90% |
| 3Y CAGR | — | -70.70% |
| 5Y CAGR | — | -61.20% |
| 10Y CAGR | — | -47.30% |
| Since inception (12 years) | -99.9% | -42.70% |
CTXR key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 10/02/2014
- Distribution frequency
- None
- Last close
- $0.46 (as of 2026-10-16)
- Market cap
- $12,628,182
- Average volume
- 140706.0
- Payment date
- 06/09/2017
- Beta
- 1.0
- Payout ratio
- 0.0%
- Forward P/E
- 0.3181
- EPS
- $-1.75
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
CTXR risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 74.7%.
Who may consider CTXR — and who may not
It is a weaker fit for investors who need monthly cash flow (CTXR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on CTXR
Frequently asked questions
Does CTXR pay monthly?
No. CTXR does not currently distribute.
When does CTXR pay a dividend?
CTXR does not currently distribute. The payment date is 06/09/2017.
How has CTXR performed?
Total return is -99.9% over the past 12 years, 479.1 points behind SPY at 379.2%. Over the past year its total return — price change plus distributions reinvested — is -68.9%. Its deepest 1-year drawdown was 74.7%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.